ALKS Share Price Performance
US$29.28
-6.00 (-17.01%)
32.9% undervalued intrinsic discount
US$43.65
Fair Value
Price US$29.28
AnalystConsensusTarget US$43.65
AnalystHighTarget US$57.14
AnalystLowTarget US$30.00
Fair ValueUS$43.65
Share Pricen/a
Alkermes plc Stock Price
- 3 Narratives written by author
- 1 Comments on narratives written by author
- 21 Fair Values set on narratives written by author
ALKS Community Narratives
AN
Fair Value US$43.65 32.9% undervalued intrinsic discount
Analyst Commentary Highlights Growth Prospects and Risks Following Alkermes Acquisition and Updated Valuation
0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
AN
Fair Value US$57.14 48.8% undervalued intrinsic discount
Expanding Mental Health Demand Will Spur Therapy Adoption Despite Risks
0users have liked this narrative
1users have commented on this narrative
3users have followed this narrative
AN
Fair Value US$30 2.4% undervalued intrinsic discount
Neuropsychiatric Treatments Will Face Regulatory Setbacks Yet Yield Progress
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Analyst Commentary Highlights Growth Prospects and Risks Following Alkermes Acquisition and Updated Valuation
Key Takeaways Expanding demand and market penetration for proprietary neuroscience products, paired with commercial execution, are fueling top-line growth and increasing operating leverage. Diversified pipeline progress, margin expansion, and financial strength provide flexibility for pipeline acceleration, external growth, and sustained earnings while minimizing dilution risk.Read more
316
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
AN
US$43.65
32.9% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
11.58% p.a.
Profit Margin
12.41%
Future PE
36.71x
Price in 2029
US$54.29
Expanding Mental Health Demand Will Spur Therapy Adoption Despite Risks
Key Takeaways Alixorexton's unique efficacy and label expansion opportunities could drive Alkermes' long-term growth well beyond current expectations, positioning it for new market entry. Exceptional early execution in psychiatry products and robust financial health provide flexibility for strategic moves and sustained margin expansion.Read more
51
users have viewed this narrative0users have liked this narrative
1users have commented on this narrative
3users have followed this narrative
AN
US$57.14
48.8% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
17.47% p.a.
Profit Margin
26.22%
Future PE
18.87x
Price in 2029
US$73.6
Neuropsychiatric Treatments Will Face Regulatory Setbacks Yet Yield Progress
Key Takeaways Reliance on a narrow product range and increased drug pricing pressures threaten long-term revenue stability and profitability. High R&D spending and market competition may limit successful commercialization and margin expansion despite innovative clinical pipeline advances.Read more
10
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$30
2.4% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
-4.85% p.a.
Profit Margin
14.17%
Future PE
35.16x
Price in 2028
US$36.85
Trending Discussion
Recently Updated Narratives
AN
ALKS: Emerging Sleep Franchise And Orexin Program Will Drive Future Upside
Fair Value: US$43.65 32.9% undervalued intrinsic discount
8 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
ALKS: Avadel Sleep Deal And Orexin Breakthrough Designation Will Drive Upside
Fair Value: US$57.14 48.8% undervalued intrinsic discount
3 followersusers have followed this narrative
1 commentusers have commented on this narrative
0 likesusers have liked this narrative
AN
Neuropsychiatric Treatments Will Face Regulatory Setbacks Yet Yield Progress
Fair Value: US$30 2.4% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Alkermes plc Key Details
About ALKS
- Founded
- 1987
- Employees
- 2050
- CEO
- WebsiteView website
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
